Equities

Synektik SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Synektik SA

Actions
Health CareMedical Equipment and Services
  • Price (PLN)297.00
  • Today's Change1.00 / 0.34%
  • Shares traded18.46k
  • 1 Year change+30.84%
  • Beta0.6181
Data delayed at least 15 minutes, as of Feb 16 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Synektik SA is a Poland-based company active in the medical sector. It produces PACS software which allows running a diagnostic imaging laboratory. It runs a research laboratory which performs acceptance and specialist tests of X-ray equipment. The Company sells medical equipment and operates a services center for imaging equipment. Synektik SA is a partner of Siemens. On November 28, 2013, the Company raised its stake in Miedzynarodowe Centra Medyczne Inwestycje Sp z o o to 100%.

  • Revenue in PLN (TTM)527.06m
  • Net income in PLN94.61m
  • Incorporated2011
  • Employees203.00
  • Location
    Synektik SAul. Jozefa Piusa Dziekonskiego 3WARSZAWA 00-728PolandPOL
  • Phone+48 223270900
  • Fax+48 228498055
  • Websitehttps://www.synektik.com.pl/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Medistim ASA249.75m53.20m1.32bn154.0024.788.4320.955.297.797.7936.5622.911.250.76799.674,341,637.0026.7221.9833.0927.1981.2178.6621.3020.322.03--0.048485.046.889.120.00878.1112.5316.89
CellaVision AB301.81m60.87m1.45bn236.0023.904.1219.024.826.426.4231.8237.210.72012.026.80--14.5214.7116.2216.9668.5068.3820.1719.852.9725.880.028141.974.949.998.7811.3420.7629.67
COLTENE Holding AG1.11bn66.16m1.52bn1.18k22.963.6315.601.372.402.4040.2215.131.311.346.40204,684.507.8010.5914.2618.4366.1162.195.957.640.70437.620.360685.663.06-1.7971.310.4306-15.4510.76
IVF Hartmann Holding AG736.97m87.91m1.61bn309.0018.312.3914.382.187.927.9266.3960.570.89643.287.88526,221.1010.697.9012.919.6855.7154.0611.939.133.79--0.004248.547.332.8534.0210.78-28.9419.92
Ion Beam Applications SA2.51bn71.60m1.97bn2.10k27.163.8015.840.78270.56770.567720.174.060.97562.733.28281,693.602.781.5012.034.6431.2134.392.852.150.62097.410.363170.816.7512.01201.573.997.6925.86
Revenio Group Oyj461.96m73.27m2.09bn247.0028.444.3122.764.520.6540.6544.124.310.75153.057.26444,129.6011.9214.0014.2317.4070.9270.9515.8619.381.639.660.0969--5.9712.43-5.935.4222.19--
Lumibird SA909.38m45.17m2.20bn1.07k48.802.6217.202.420.47750.47759.618.900.50770.95934.42202,198.502.522.513.113.1763.8961.894.974.901.643.160.45830.001.7513.34-20.08-8.3815.27--
medmix AG2.16bn-26.81m2.22bn2.67k--1.129.881.03-0.1696-0.169611.6010.390.47073.565.86174,403.90-0.49271.27-0.61991.5534.5235.24-1.052.651.101.870.4268140.79-0.55492.84-2,566.67--6.02--
RaySearch Laboratories AB (publ)534.56m90.57m2.27bn458.0027.896.4511.014.256.656.6539.2528.740.65846.252.932,935,074.0011.165.2616.217.7792.4291.0116.949.701.6664.920.286152.3812.7715.5811.93--0.2213--
Advanced Medical Solutions Group plc1.07bn44.18m2.31bn1.50k52.051.8615.682.160.04170.04171.011.170.57582.095.57137,690.002.385.092.635.5252.1955.064.1411.151.553.880.242833.4740.6611.64-55.35-17.818.3610.90
Xvivo Perfusion AB322.96m10.01m2.32bn198.00232.322.7661.147.180.79680.796825.7667.100.340.89396.134,101,844.001.053.281.123.5273.8173.863.1010.873.681.830.05570.00-1.2535.19-85.39------
Synektik SA527.06m94.61m2.52bn203.0026.6811.3323.684.7911.099.2061.8026.121.2211.183.60--21.9620.1136.1032.6734.9831.4017.9513.601.4142.090.153--9.1640.2951.5870.0228.82--
Arjo AB (publ)4.37bn132.82m2.73bn6.94k22.020.98624.810.62381.231.2340.3927.380.7044.926.221,584,702.002.143.262.914.8042.5943.423.044.780.84944.190.417948.74-2.593.92-32.93-8.68--2.25
Gerresheimer AG9.48bn98.33m2.89bn13.54k29.420.49012.460.30530.6760.67665.1540.590.54553.737.85185,328.900.63413.300.87164.6826.8930.041.165.840.52142.080.602241.292.287.90-5.526.3217.58-49.35
Paul Hartmann AG10.22bn343.23m3.29bn10.09k9.540.66354.060.322422.9522.95682.93330.051.161.975.54240,745.704.124.215.455.7959.5657.303.563.351.1114.110.246537.952.321.95281.5813.2310.082.71
GVS SpA1.78bn96.29m3.33bn4.23k31.641.8311.631.870.13230.13232.352.280.4752.027.0199,768.772.576.013.338.5356.1157.985.4111.160.75672.400.4234--0.895913.51144.520.172923.38--
Data as of Feb 16 2026. Currency figures normalised to Synektik SA's reporting currency: Polish New Zloty PLN

Institutional shareholders

18.02%Per cent of shares held by top holders
HolderShares% Held
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne SAas of 30 Sep 2025724.76k8.50%
Norges Bank Investment Managementas of 30 Jun 2025348.09k4.08%
Generali PTE SAas of 31 Dec 2024171.30k2.01%
Dimensional Fund Advisors LPas of 05 Feb 202679.13k0.93%
Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SAas of 30 Jun 202544.75k0.53%
Carnegie Fonder ABas of 30 Dec 202541.10k0.48%
Discover Capital GmbHas of 31 Oct 202540.00k0.47%
IPOPEMA TFI SAas of 30 Jun 202538.50k0.45%
Swedbank Robur Fonder ABas of 30 Jan 202625.00k0.29%
AgioFunds TFI SAas of 28 Jan 202624.04k0.28%
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.